Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy

Angew Chem Int Ed Engl. 2016 Jun 13;55(25):7091-7094. doi: 10.1002/anie.201601273. Epub 2016 May 3.

Abstract

RNA interference (RNAi) gene silencing technologies have shown significant potential for treating various diseases, including cancer. However, clinical success in cancer therapy remains elusive, mainly owing to suboptimal in vivo delivery of RNAi therapeutics such as small interference RNA (siRNA) to tumors. Herein, we developed a library of polymers that respond to a narrow pH change (ultra-pH-responsive), and demonstrated the utility of these materials in targeted and deep tumor-penetrating nanoparticle (NP) for in vivo RNAi. The new NP platform is mainly composed of the following key components: i) internalizing RGD (iRGD) to enhance tumor targeting and tissue penetration; ii) polyethylene glycol (PEG) chains to prolong blood circulation; and iii) sharp pH-responsive hydrophobic polymer to improve endosome escape. Through systematic studies of structure-function relationship, the optimized RNAi NPs (<70 nm) showed efficient gene silencing and significant inhibition of tumor growth with negligible toxicities in vivo.

Keywords: cancer therapy; nanoparticles; pH-responsive; siRNA delivery; tumor penetration.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Cell Line, Tumor
  • Delayed-Action Preparations / chemistry*
  • Gene Transfer Techniques*
  • HeLa Cells
  • Humans
  • Hydrogen-Ion Concentration
  • Inhibitor of Apoptosis Proteins / genetics
  • Nanoparticles / chemistry*
  • Neoplasms / genetics
  • Neoplasms / therapy*
  • Oligopeptides / chemistry
  • Polyethylene Glycols / chemistry
  • Polymers / chemistry
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / pharmacokinetics
  • RNA, Small Interfering / therapeutic use
  • RNAi Therapeutics / methods*
  • Survivin

Substances

  • BIRC5 protein, human
  • Delayed-Action Preparations
  • Inhibitor of Apoptosis Proteins
  • Oligopeptides
  • Polymers
  • RNA, Small Interfering
  • Survivin
  • Polyethylene Glycols
  • arginyl-glycyl-aspartic acid